Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763455 | 0.88 | EPHX2 (0.42) | EPHX2CDK9PTGER1SLC2A2MAPK1 | |
| SCHEMBL339710 | 0.84 | DPP4 (0.41) | EPHX2CDK9PTGER1SLC2A2KCNJ6 | |
| SCHEMBL339781 | 0.83 | ALDH1A1 (0.38) | ALDH1A1IDO1 | |
| SCHEMBL338256 | 0.80 | IDO1 (0.40) | ALDH1A1MAPK1CNR2IDO1 | |
| SCHEMBL339005 | 0.80 | IDO1 (0.40) | ALDH1A1EPHX2CNR2IDO1 | |
| SCHEMBL337927 | 0.79 | IDO1 (0.39) | ALDH1A1MAPK1CNR2IDO1 | |
| SCHEMBL1919688 | 0.77 | ALDH1A1 (0.38) | ALDH1A1SLC2A2IDO1 | |
| SCHEMBL339213 | 0.77 | IDO1 (0.38) | ALDH1A1EPHX2IDO1 | |
| SCHEMBL339323 | 0.77 | ALDH1A1 (0.38) | ALDH1A1EPHX2IDO1 | |
| SCHEMBL338980 | 0.76 | IDO1 (0.39) | ALDH1A1CNR2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | ALDH1A1 480/4885EPHX2 3864/4885CDK9 1700/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | ALDH1A1 480/4885EPHX2 3864/4885CDK9 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.